medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 6

<< Back Next >>

Ann Hepatol 2018; 17 (6)

Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives?

Noor S, Ismail M, Haider I, Khadim F

Language: English
References: 36
Page: 1001-1011
PDF size: 214.57 Kb.


ABSTRACT

Introduction and aim. Hepatitis patients usually present with comorbidities and polypharmacy which increases risk of potential drug-drug interactions (pDDIs). We explored frequency, levels, predictors, and clinical relevance of pDDIs in hospitalized hepatitis patients. Material and methods. Retrospective cohort study was used. Clinical profiles of 413 hepatitis patients were reviewed for pDDIs using Micromedex-DrugReax. Frequency, levels and clinical relevance of pDDIs were reported. Logistic regression analysis was used to calculate odds-ratios for predictors. Results. Of total 413 patients, pDDIs were reported in 55.2%. Major-pDDIs were found in 35% patients. Total 660 pDDIs were identified, of which, 304 (46%) were of major-severity and 299 (45%) of moderateseverity. Patient’s profiles of top-10 major-pDDIs were presented with signs/symptoms such as fever, hepatomegaly, anorexia, jaundice, hypertension, tachycardia, bradycardia, & pedal edema; and abnormalities in labs such as electrolytes-level, alanine aminotransferase, blood urea nitrogen, bilirubin-level, & serum creatinine. Significant association was observed for the presence of pDDIs with › 9 prescribed medicines (p ‹ 0.001), hospitalization of › 5 days (p = 0.03), and stroke as comorbidity (p = 0.05). Moreover, odds of exposure to major-pDDIs were significantly higher in patients taking › 9 prescribed medicines (p ‹ 0.001), hospitalization of › 5 days (p = 0.002), and stroke as comorbidity (p = 0.002). Conclusion. We observed hepatitis patients presented with a considerable number of clinically relevant pDDIs. Attention should be given to widespread major-pDDIs and their potential adverse outcomes. Clinically relevant parameters, such as labs and signs/symptoms should be monitored particularly in high risk patients having polypharmacy, prolong hospitalization, and stroke as comorbidity.


REFERENCES

  1. Sembulingam K, Sembulingam P. (eds.) Essentials of Medical Phsyiology. 2nd Ed. New Dehli, India: Jaypee Brothers Medical Publishers, 2012; pp. 179-88.

  2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.

  3. Delco F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease. Drug Saf 2005; 28: 529-45.

  4. Blaschke TF, Rubin PC. Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet 1979; 4: 423-32.

  5. Vyas K, Gala B, Sawant P, Das HS, Kulhalli PM, Mahajan SS. Assessment of portal hemodynamics by ultrasound color Doppler and laser Doppler velocimetry in liver cirrhosis. Indian J Gastroenterol 2001; 21: 176-8.

  6. Adedoyin A, Arns PA, Richards WO, Wilkinson GR, Branch RA. Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6. Clin Pharmacol Ther 1998; 64: 8-17.

  7. Wioeniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drugdrug interactions and QT prolongation as a commonly assessed cardiac effect-comprehensive overview of clinical trials. BMC Pharmacol Toxicol 2016; 17: 12.

  8. Ginès P, Arrovo V, Rodés J. Pharmacotherapy of ascites associated with cirrhosis. Drugs 1992; 43: 316-32.

  9. Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt L-A, Miller C. A cross-sectional study comparing the frequency of drug interactions after adding simeprevir-or sofosbuvir-containing therapy to medication profiles of hepatitis C monoinfected patients. Infect Dis Ther 2015; 4: 67-78.

  10. Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol 2014; 26: 1073-82.

  11. Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, et al. Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. J Hepatol 2013; 58: 792-800.

  12. Franz CC, Egger S, Born C, Bravo AER, Krähenbühl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol 2012; 68: 179-88.

  13. Back D, Else L. The importance of drug–drug interactions in the DAA era. Dig Liver Dis 2013; 45: S343-S348.

  14. Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One 2017; 12: e0172159.

  15. Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin M-A, Cuzin L, Billaud E, Cheret A, et al. Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients. PLoS One 2015; 10: e0141164.

  16. Micromedex Drug-Reax®, Greenwood Village, CO: Truven Health Analytics. Available at: https:// www.micromedexsolutions.com/micromedex2/librarian/ssl/ true. Accessed February 10 2017.

  17. Patel RI, Beckett RD. Evaluation of resources for analyzing drug interactions. J Med Libr Assoc 2016; 104: 290-5.

  18. Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract 2016; 5: 257-63.

  19. Tatro DS. (ed.) Drug Interaction Facts: Facts and Comparisons. St. Louis, Missouri: Wolters Kluwer Health, 2008; pp. 901-1358.

  20. Baxter K. (ed.) Stockley’s Drug Interactions. 9th ed. London, Chicago: Pharmaceutical Press; 2010; pp.349-1123.

  21. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med 2008; 19: 413-20.

  22. Ibáñez A, Alcalá M, García J, Puche E. Drug-drug interactions in patients from an internal medicine service. Farm Hosp 2008; 32: 293-297.

  23. Ismail M, Iqbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, Gul Q, et al. Potential drug–drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm 2013; 35: 455-62.

  24. Ismail M, Aziz S, Noor S, Haider I, Shams F, Haq I, Khadim F, et al. Potential drug-drug interactions in pediatric patients admitted to intensive care unit of Khyber Teaching Hospital, Peshawar, Pakistan: A cross-sectional study. J Crit Care 2017; 40: 243-50.

  25. Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017; 23: 1618-26.

  26. Moura CS, Prado NM, Belo NO, Acurcio FA. Evaluation of drug–drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm 2012; 34: 547-52.

  27. Geerts AF, De Koning FH, De Smet PA, Van Solinge WW, Egberts TC. Laboratory tests in the clinical risk management of potential drug-drug interactions. Drug Saf 2009; 32: 1189- 97.

  28. van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee- Zuiderwijk WJ, Smits P, Brouwers JR. Clinical relevance of drug-drug interactions. Drug Saf 2005; 28: 1131-9.

  29. Egger SS, Drewe J, Schlienger RG. Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58: 773-8.

  30. Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int 2015; 35: 35- 43.

  31. Moura CSd, Acurcio FdA, Belo NdO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharmaceut Sci 2009; 12: 266-72.

  32. Caratozzolo S, Gipponi S, Marengoni A, Pari E, Scalvini A, Pasina L, Magoni M, et al. Potentially Serious Drug-Drug Interactions in Older Patients Hospitalized for Acute Ischemic and Hemorrhagic Stroke. Eur Neurol 2016; 76: 161-6.

  33. Gagne J, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther 2008; 33: 141-51.

  34. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002; 40: 1161-71.

  35. Roberts JS, Watrous ML, Schulz RM, Mauch RP, Nightengale BS. Quantifying the Clinical Significance of Drug—Drug Interactions: Scaling Pharmacists’ Perceptions of a Common Interaction Classification Scheme. Ann Pharmacother 1996; 30: 926-34.

  36. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51-9.




2020     |     www.medigraphic.com